Enzalutamide Adds 5 Months Survival In Late-Stage Prostate Cancer
8/19/2012
Results of a phase III clinical trial of the drug Enzalutamide, published recently in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer. "This is a major advance. Not only do we see more survival benefit than from traditional chemotherapy, but the side effects of Enzalutamide are much lower...
Researchers at Moffitt Cancer Center, working with colleagues in Sweden, the Netherlands and Puerto Rico, have validated a radiosensitivity molecular signature that can lead to better radiation therapy decisions for treating patients with breast cancer. The results appeared in a recent issue of Clinical Cancer Research, a publication of the American Association for Cancer Research...
Malignant Brain Cancer Antigens Targeted By Vaccine Which Significantly Lengthens Survival
8/19/2012
An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy, published online. Median survival in a Phase I clinical trial at Cedars-Sinai's Johnnie L. Cochran, Jr. Brain Tumor Center was 38...
Added Benefit Of Eribulin In Breast Cancer Is Not Proven
8/19/2012
Eribulin (trade name: Halaven®) was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy...
Fourth Drug In 2 Years Extends Life In Patients With Prostate Cancer
8/18/2012
The head of one of the UK's leading cancer research organisations has hailed a golden age in prostate cancer drug discovery as for the fourth time in two years results are published finding a new drug can significantly extend life...
Cervical Disease Treatment Is Not Associated With Preterm Birth Risk
8/17/2012
A study published online in theBritish Medical Journal reveals that treatment for cervical disease does not seem to raise the risk of premature deliveries after treatment. The study is the largest in the UK assessing the risks and the findings are contradictory to earlier studies, which indicated that treatment would increase the risk of premature deliveries...
Cervical Disease Treatment Is Not Associated With Preterm Birth Risk
8/17/2012
A study published online in theBritish Medical Journal reveals that treatment for cervical disease does not seem to raise the risk of premature deliveries after treatment. The study is the largest in the UK assessing the risks and the findings are contradictory to earlier studies, which indicated that treatment would increase the risk of premature deliveries...
Density Of Breasts Does Not Impact Death Among Breast Cancer Patients
8/17/2012
A study featured in the August 20 edition in the Journal of the National Cancer Institute reveals that the risk of mortality from breast cancer is not associated with high mammographic breast density in breast cancer patients...
Nanoparticles Shrink Ovarian Cancer Tumors In Mice
8/17/2012
By sequencing cancer-cell genomes, researchers have found a substantial amount of genes that happen to be mutated, deleted or duplicated within cancerous cells. This treasure chest is a great asset for scientists searching for innovative drug targets, however, it's extremely difficult to examine all of them promptly...
Common Antibiotics Are Not Always Best
8/17/2012
A new study, appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN), has evidence that the most commonly used antibiotic treating bloodstream infections in dialysis patients, vancomycin, might not be the best choice...